Daptomycin Drug Market Trend Shows a Rapid Growth by 2030 According to New Research Report

Global Daptomycin Drug Market: Introduction

Daptomycin drug medication is an antibiotic used to treat serious bacterial infections. It stops the growth of bacteria. Dosage is based on the patient’s weight, medical condition, and response to treatment. In children, the dosage is also based on age and weight. The drug is not recommended for children below the age of 12 months.

Read Report Overview – https://www.transparencymarketresearch.com/daptomycin-drug-market.html

Daptomycin has numerous FDA-approved and off-label clinical uses, such as complicated skin and skin structure infections (cSSSI) in adult and pediatric patients and S. aureus bacteremia in adult patients, including those with right-sided infective endocarditis. Daptomycin is a cyclic lipopeptide antibiotic that exerts its bactericidal effect by disrupting multiple aspects of bacterial cell membrane function.

Rise in infections in the bloodstream

Bloodstream infections are infective endocarditis, central venous catheter-associated bloodstream infections, primary bacteremia, and those with secondary bacteremia due to focal infections including abscesses, osteomyelitis, urinary tract infections, or pneumonia. An infectious pathogen reaches the bloodstream by direct invasion into blood vessels, via lymphatic vessels, draining a focus of infection such as an abscess or through vascular devices such as needles of catheters.

Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79443

Slurred speech or confusion, extreme shivering or muscle pain, oliguria, respiratory problems, and a pale skin with a falling blood pressure are all symptoms potentially associated with initial sepsis. Bloodstream infections (BSIs) are among the highly severe human infections, with markedly high rates of morbidity and mortality.

Rise of right-sided infective endocarditis

According to Annals of Cardiothoracic Surgery, Right-sided infective endocarditis (RSIE) is less common than left-sided infective endocarditis (IE), are only 5% to 10% of cases of IE. Endocarditis affecting the right heart chambers and valves has typical etiologies and epidemiology as well as unique diagnostic and therapeutic options. Right-sided infective endocarditis is due to intravenous drug abuse. Right-sided infective endocarditis related to drug abuse mostly affects the tricuspid valve and rarely the pulmonary valve.

Request for Analysis of COVID-19 Impact on Daptomycin Drug Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79443

According to IntechOpen, in the U.S., North Carolina, a study reported a 12-fold increase in hospitalizations for intravenous drug use related IE over the last decade. Right-sided infective endocarditis (RSIE) can be classified into three epidemiological groups: intravenous drug users (IDUs), intravascular device carriers, and the ‘three noes’ group that is no left-sided, no device, no IDUs.

North America to Account for Major Share of Global Daptomycin Drug Market

North America is projected to account for major share of the global daptomycin drug market during the forecast period. The market in the region is anticipated to expand at a rapid pace in the next few years due to an increase in research & development and various government initiatives. Europe is expected to be the second-largest market during the forecast period.

The daptomycin drug market in Asia Pacific is likely to expand at a high CAGR during the forecast period. This can be attributed to a rise in investment in research & development by private & government organizations and increase in healthcare management.

Pre Book Daptomycin Drug Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79443&ltype=S

Key Players Operating in Global Daptomycin Drug Market

The global daptomycin drug market is highly consolidated owing to the presence of numerous key players. Leading players operating in the global daptomycin drug market include:

  • Teva Pharmaceutical Industries Ltd.
  • Merck &co.
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy’s Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings A/S

More Trending Reports by Transparency Market Research –

Teleradiology Market: https://www.prnewswire.co.uk/news-releases/rising-adoption-of-mhealth-technologies-changing-the-face-of-teleradiology-market-global-revenues-to-expand-at-cagr-of-16-9-from-2019-to-2027-says-tmr-891058992.html

Antibleeding Gel Market: https://www.biospace.com/article/antibleeding-gel-market-increasing-incidences-of-road-accidents-to-drive-the-market/

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/